CliffBio
biologic

Maci

autologous cultured chondrocytes on porcine collagen membrane

Loss of exclusivityDecember 2028projected — 12-year biologic exclusivity estimate
CompanyVericel Corporation →View the full company profile on CliffBio

Drug detail

Brand nameMaci
Active ingredientautologous cultured chondrocytes on porcine collagen membrane
Strength500,000 CM2 CM2
Dosage formCell Sheets
RouteImplantation
ModalityBiologic
FDA approvalDecember 2016
Marketing statusRx

More from Vericel Corporation

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Maci patent cliff — loss of exclusivity December 2028 | CliffBio